Prestige Consumer Healthcare Valuation
Is P2BH34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of P2BH34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: P2BH34 (R$60.45) is trading below our estimate of fair value (R$88.8)
Significantly Below Fair Value: P2BH34 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for P2BH34?
Other financial metrics that can be useful for relative valuation.
What is P2BH34's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$3.05b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.8x |
Enterprise Value/EBITDA | 11.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does P2BH34's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.6x | ||
HYPE3 Hypera | 2.3x | 9.4% | R$18.2b |
OFSA3 Ouro Fino Saúde Animal Participações | 1.1x | 12.5% | R$1.0b |
600380 Joincare Pharmaceutical Group IndustryLtd | 1.3x | 7.5% | CN¥20.9b |
600062 China Resources Double-Crane PharmaceuticalLtd | 1.9x | 8.6% | CN¥20.0b |
P2BH34 Prestige Consumer Healthcare | 2.8x | 2.1% | R$3.1b |
Price-To-Sales vs Peers: P2BH34 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does P2BH34's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Sales vs Industry: P2BH34 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the Global Pharmaceuticals industry average (2.3x).
Price to Sales Ratio vs Fair Ratio
What is P2BH34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.8x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate P2BH34's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.